Intensive Care Unit, Hospital Sao Rafael, Salvador, Brazil.
Palliative Care Team, Hospital Sao Rafael, Salvador, Brazil.
J Palliat Med. 2019 Sep;22(9):1099-1105. doi: 10.1089/jpm.2018.0554. Epub 2019 Apr 11.
Legal concerns have been implicated in the occurrence of variability in decisions of limitations of medical treatment (LOMT) before death. We aimed to assess differences in perceptions between physicians and prosecutors toward LOMT. We sent a survey to intensivists, oncologists, and prosecutors from Brazil, from February 2018 to May 2018. Respondents rated the degree of agreement with withholding or withdrawal of therapies in four different vignettes portraying a patient with terminal lung cancer. We measured the difference in agreement between respondents. There were 748 respondents, with 522 (69.8%) intensivists, 106 (14.2%) oncologists, and 120 (16%) prosecutors. Most respondents agreed with withhold of chemotherapy (95.2%), withhold of mechanical ventilation (MV) (90.2%), and withdrawal of MV (78.4%), but most (75%) disagreed with withdrawal of MV without surrogate's consent. Prosecutors were less likely than intensivists and oncologists to agree with withhold of chemotherapy (95.7% vs. 99.2% vs. 100%, respectively, < 0.001) and withhold of MV (82.4% vs. 98.3% vs. 97.9%, respectively, < 0.001), whereas intensivists were more likely to agree with withdrawal of MV than oncologists (87.1% vs. 76.1%, = 0.002). Moreover, prosecutors were more likely to agree with withholding of active cancer treatment than with withholding of MV [difference (95% confidence interval, CI) = 13.2% (5.2 to 21.6), = 0.001], whereas physicians were more likely to agree with withholding than with withdrawal of MV [difference (95% CI) = 10.9% (7.8 to 14), < 0.001]. This study found differences and agreements in perceptions toward LOMT between prosecutors, intensivists, and oncologists, which may inform the discourse aimed at improving end-of-life decisions.
法律问题已被牵涉到死亡前治疗限制决策的可变性中。我们旨在评估医生和检察官对治疗限制决策的看法差异。我们于 2018 年 2 月至 5 月期间向来自巴西的重症监护医生、肿瘤医生和检察官发送了一份调查。受访者对四个不同的案例描述中的一位患有终末期肺癌的患者的治疗方案进行了评价,以评估他们在四种不同情况下的治疗方案的同意程度。我们衡量了受访者之间的同意程度差异。共有 748 名受访者,其中 522 名(69.8%)为重症监护医生,106 名(14.2%)为肿瘤医生,120 名(16%)为检察官。大多数受访者同意停止化疗(95.2%)、停止机械通气(MV)(90.2%)和停止 MV(78.4%),但大多数(75%)不同意在未经代理人同意的情况下停止 MV。与重症监护医生和肿瘤医生相比,检察官不太可能同意停止化疗(95.7%比 99.2%比 100%,均 < 0.001)和停止 MV(82.4%比 98.3%比 97.9%,均 < 0.001),而重症监护医生比肿瘤医生更有可能同意停止 MV(87.1%比 76.1%, = 0.002)。此外,检察官更有可能同意停止积极的癌症治疗,而不是停止 MV[差异(95%置信区间,CI)=13.2%(5.2 到 21.6), = 0.001],而医生更有可能同意停止 MV,而不是停止 MV[差异(95%CI)=10.9%(7.8 到 14), < 0.001]。本研究发现检察官、重症监护医生和肿瘤医生对治疗限制决策的看法存在差异和共识,这可能为旨在改善临终决策的讨论提供信息。